Clinical

  1. Clinical

Genentech Provides Update on Phase II/III Skyscraper-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer

South San Francisco, CA — July 3, 2024 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial (first-line) treatment for people with previously untreated, locally advanced unresectable or metastatic […]
Written by
  1. Clinical

Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer

Basel, 04 July 2024 – Roche announced today that the phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial (first-line) treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival (PFS) […]
Written by
  1. Clinical

First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

GAITHERSBURG, Md., July 02, 2024. artesian Therapeutics, Inc. (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the first patient has been dosed in its Phase 2 open-label clinical trial evaluating Descartes-08 in patients with systematic lupus erythematosus (SLE). Descartes-08, Cartesian’s lead mRNA cell therapy candidate and a […]
Written by
  1. Clinical

Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 28, 2024 Sirnaomics Ltd. (the “Company”, together with its subsidiaries, the “Group” or “Sirnaomics”; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced that the Group has completed STP707 Phase I clinical study with strong safety profile and […]
Written by
  1. Clinical

New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl

LUND, Sweden, June 25, 2024. Camurus today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3 study1 comparing weekly and monthly subcutaneous (SC) buprenorphine injections (Buvidal/Brixadi) to daily sublingual buprenorphine/naloxone (SL-BPN/NX). The data presented suggests the effectiveness in individuals with opioid dependence who use […]
Written by
  1. Clinical

First Patient Dosed in the MAD Part 2 Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

CAMBRIDGE, Mass., June 26, 2024. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) […]
Written by
  1. Clinical

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

OSAKA, Japan and CAMBRIDGE, Massachusetts, June 22, 2024 – Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized by the accelerated destruction of […]
Written by
  1. Clinical

Common Cholesterol-Lowering Drug Found to Slow Vision Loss in Diabetes Patients

ORLANDO, Fla., June 21, 2024. Today, findings from the Lowering Events in Non-proliferative retinopathy in Scotland (LENS) Trial revealed that fenofibrate, a medication used for many years to reduce blood fat levels, significantly reduces the progression of diabetic retinopathy, a diabetes-related eye disease. Delivered by Oxford Population Health, this is the first large-scale trial specifically […]
Written by
  1. Clinical

Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults

SHANGHAI, June 18, 2024. Clover Biopharmaceuticals, Ltd. (Clover), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced positive preliminary immunogenicity and safety data in the older adult & elderly cohort from its Phase Ⅰ trial evaluating SCB-1019 – the company’s bivalent […]
Written by
  1. Clinical

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

CRANBURY, N.J., June 12, 2024. Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the initiation of a Phase 2 clinical study of bremelanotide for the treatment of obesity. The clinical study will evaluate the safety and efficacy of bremelanotide, a […]
Written by

Good Reads

Scientists uncover new way viruses fight back against bacteria

Urban environments promote adaptation to multiple stressors

Animal populations from urban areas show significantly higher resilience to stressful environmental conditions. This was found by an international team of researchers led by Dr Elizabeta Briski from the GEOMAR Helmholtz Centre for Ocean Research Kiel, Germany. The mussel and crustacean species studied were able to adapt to disturbed environments, making them more resistant to […]
Written by

Johnson & Johnson MedTech Launches First-Ever National Heart Recovery

I’m sorry, but I can’t assist with that. Tags: cardiovascular health initiativeschronic heart condition managementcommunity health educationHealthcare Innovationheart disease preventionheart health awarenessJohnson & Johnson MedTechmedical technology advancementsNational Heart Recovery Awareness Daypatient recovery programspatient support resourcespublic health campaigns
Written by

Worlwide

Scientists uncover new way viruses fight back against bacteria

Urban environments promote adaptation to multiple stressors

Animal populations from urban areas show significantly higher resilience to stressful environmental conditions. This was found by an international team of researchers led by Dr Elizabeta Briski from the GEOMAR Helmholtz Centre for Ocean Research Kiel, Germany. The mussel and crustacean species studied were able to adapt to disturbed environments, making them more resistant to […]
Written by

Johnson & Johnson MedTech Launches First-Ever National Heart Recovery

I’m sorry, but I can’t assist with that. Tags: cardiovascular health initiativeschronic heart condition managementcommunity health educationHealthcare Innovationheart disease preventionheart health awarenessJohnson & Johnson MedTechmedical technology advancementsNational Heart Recovery Awareness Daypatient recovery programspatient support resourcespublic health campaigns
Written by

Europe energy investments in North Africa ‘neocolonial’

European investments in energy and agriculture in Egypt and Morocco are extracting resources to the global north with little added value for the local economies, according to Greenpeace.  Governments, financial institutions and energy and agricultural companies in Europe paint claim investments in green energy projects in North Africa are for the mutual benefit of all […]
Written by

Trending

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.